Among the more than 20,000 drugs approved by the FDA, there may be some that can treat COVID-19. A team at the University of California, San Francisco, is identifying possible candidates.
Academic rigor, journalistic flair
Articles on Drug discovery
Displaying 21 - 37 of 37 articles
Pathogens rapidly evolve resistance to antibiotics. AI could keep us a step ahead of deadly infections.
As antibiotic resistance increases globally, the heat is on to find new alternatives to treat infections. Chemists can get a head start by looking at compounds produced in nature by fishes’ microbes.
Mental health is impacted by both genetic and environmental factors. But new research reveals that many mental health disorders may flow from early disturbances in fetal development.
Using a large number of computers to screen TB drugs reduces the cost and time.
People with Down syndrome are at much higher risk of dementia than the general population. Knowing when cognitive changes start is critical for developing new drugs.
Small-batch brewers are starting to tinker with biologic drugs to meet their own medical needs. A side effect of their success would be a disruption to how big pharma makes and distributes drugs.
There’s a common, popular and well-studied method to ensure new technologies are safe and effective for public use – even if researchers don’t fully understand how they work.
Pharmaceutical companies focus on small molecules they’ve devised – and can easily patent. But nature’s already come up with many antibacterial compounds that drug designers could use to make medicines.
Medicinal chemists are tweaking a natural molecule that can be a deadly poison – a modified version might work as a nonhormonal male contraceptive.
Researchers use an algorithm designed to help robots move to figure out what’s possible when designing new molecules in a promising class of pharmaceuticals.
Because we’re still not sure exactly what causes dementia, finding a treatment is difficult.
By exploiting the way yeast cells mate, researchers have figured out a quicker, easier way to identify on- and off-target drug interactions.
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here’s where they come from and how they work.
Simpler animal models can give researchers a much clearer picture of human diseases.
With the right investment, an open source drug discovery system might compete with the traditional pharmaceutical industry to deliver the drugs we need.
Understanding how cell signalling goes wrong could lead to the development of precision cancer treatments.
Top contributors
-
Doctoral Student in Biochemistry, University of Washington
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
-
Director of Natural Product Discovery Core; Assistant Professor of Medicinal Chemistry, University of Michigan
-
Assistant Professor of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus
-
Associate professor, University of Sydney
-
PhD Student, University of Liverpool
-
Science Writer, Queensland Brain Institute, The University of Queensland
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
PhD candidate, University of Leicester
-
Professor, Abell Chair in Synthetic Biology, Colorado State University
-
Associate Professor in Mechanical Engineering, Texas A&M University
-
Virology Research Scientist, University of Washington
-
Postdoctoral Researcher in Chemical and Biological Engineering, Colorado State University
-
Professor of Medicinal Chemistry and Director of the Institute for Therapeutics Discovery and Development, University of Minnesota
-
Director, Clem Jones Centre for Ageing Dementia Research, The University of Queensland
